148 related articles for article (PubMed ID: 37965255)
61. Mapping the Early Dispersal Patterns of SARS-CoV-2 Omicron BA.4 and BA.5 Subvariants in the Absence of Travel Restrictions and Testing at the Borders in Europe.
Kostaki EG; Mossialos E; Tseti I; Sfikakis PP; Paraskevis D
Viruses; 2022 Dec; 15(1):. PubMed ID: 36680171
[TBL] [Abstract][Full Text] [Related]
62. A COVID-19 DNA Vaccine Candidate Elicits Broadly Neutralizing Antibodies against Multiple SARS-CoV-2 Variants including the Currently Circulating Omicron BA.5, BF.7, BQ.1 and XBB.
Ding Y; Fan F; Xu X; Zhao G; Zhang X; Zhao H; Wang L; Wang B; Gao XM
Vaccines (Basel); 2023 Mar; 11(4):. PubMed ID: 37112691
[TBL] [Abstract][Full Text] [Related]
63. Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75.
Wang Q; Iketani S; Li Z; Guo Y; Yeh AY; Liu M; Yu J; Sheng Z; Huang Y; Liu L; Ho DD
Cell Host Microbe; 2022 Nov; 30(11):1512-1517.e4. PubMed ID: 36108630
[TBL] [Abstract][Full Text] [Related]
64. Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants.
Duty JA; Kraus T; Zhou H; Zhang Y; Shaabani N; Yildiz S; Du N; Singh A; Miorin L; Li D; Stegman K; Ophir S; Cao X; Atanasoff K; Lim R; Mena I; Bouvier NM; Kowdle S; Carreño JM; Rivero-Nava L; Raskin A; Moreno E; Johnson S; Rathnasinghe R; Pai CI; Kehrer T; Cabral EP; Jangra S; Healy L; Singh G; Warang P; Simon V; Sordillo EM; van Bakel H; Liu Y; Sun W; Kerwin L; Teijaro J; Schotsaert M; Krammer F; Bresson D; García-Sastre A; Fu Y; Lee B; Powers C; Moran T; Ji H; Tortorella D; Allen R
Med; 2022 Oct; 3(10):705-721.e11. PubMed ID: 36044897
[TBL] [Abstract][Full Text] [Related]
65. The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review.
Sarkar A; Omar S; Alshareef A; Fanous K; Sarker S; Alroobi H; Zamir F; Yousef M; Zakaria D
Hum Vaccin Immunother; 2023 Dec; 19(1):2212568. PubMed ID: 37254497
[TBL] [Abstract][Full Text] [Related]
66. Salivary antibodies induced by BA.4/BA.5-convalescence or bivalent booster Immunoglobulin vaccination protect against novel SARS-COV-2 variants of concern.
Diem G; Dichtl S; Zaderer V; Lass-Flörl C; Reindl M; Lupoli G; Dächert C; Muenchhoff M; Graf A; Blum H; Keppler OT; Wilflingseder D; Posch W
Microbiol Spectr; 2023 Aug; 11(5):e0179323. PubMed ID: 37551989
[TBL] [Abstract][Full Text] [Related]
67. Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection.
Zhu KL; Jiang XL; Zhan BD; Wang XJ; Xia X; Cao GP; Sun WK; Huang PX; Zhang JZ; Gao YL; Dai EH; Gao HX; Ma MJ
Cell Rep; 2023 Feb; 42(2):112075. PubMed ID: 36774551
[TBL] [Abstract][Full Text] [Related]
68. Comparative Computational Analysis of Spike Protein Structural Stability in SARS-CoV-2 Omicron Subvariants.
Balupuri A; Kim JM; Choi KE; No JS; Kim IH; Rhee JE; Kim EJ; Kang NS
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003257
[TBL] [Abstract][Full Text] [Related]
69. Genomic analysis of SARS-CoV-2 omicron sublineage BA.5.2.1 in Erbil/Iraq.
Majed SO; Jalal PJ; Fatah MH; Karim KK; Karim AY; Miasko M; Hasannajad S; Mustafa SA
Cell Mol Biol (Noisy-le-grand); 2023 Nov; 69(11):56-63. PubMed ID: 38015540
[TBL] [Abstract][Full Text] [Related]
70. Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies.
Planas D; Bruel T; Staropoli I; Guivel-Benhassine F; Porrot F; Maes P; Grzelak L; Prot M; Mougari S; Planchais C; Puech J; Saliba M; Sahraoui R; Fémy F; Morel N; Dufloo J; Sanjuán R; Mouquet H; André E; Hocqueloux L; Simon-Loriere E; Veyer D; Prazuck T; Péré H; Schwartz O
Nat Commun; 2023 Feb; 14(1):824. PubMed ID: 36788246
[TBL] [Abstract][Full Text] [Related]
71. Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants.
Wang Q; Yang C; Yin L; Sun J; Wang W; Li H; Zhang Z; Chen S; Liu B; Liu Z; Shi L; Liu X; Guan S; Wang C; Qu L; Feng Y; Niu X; Feng L; Zhao J; Li P; Chen L; Zhong N
Signal Transduct Target Ther; 2023 Apr; 8(1):167. PubMed ID: 37069171
[TBL] [Abstract][Full Text] [Related]
72. Molecular Epidemiology of SARS-CoV-2 Omicron Sub-Lineages Isolated from Turkish Patients Infected with COVID-19.
Sayan M; Arikan A; Sanlidag E
Viruses; 2023 Apr; 15(5):. PubMed ID: 37243152
[TBL] [Abstract][Full Text] [Related]
73. Comparison of pneumonia severity scores for COVID-19 patients with the Omicron variant.
Miyashita N; Nakamori Y; Ogata M; Fukuda N; Yamura A; Ito T
J Infect Chemother; 2024 May; 30(5):463-466. PubMed ID: 37952841
[TBL] [Abstract][Full Text] [Related]
74. The Omicron variant of concern: The genomics, diagnostics, and clinical characteristics in children.
Setiabudi D; Sribudiani Y; Hermawan K; Andriyoko B; Nataprawira HM
Front Pediatr; 2022; 10():898463. PubMed ID: 35983081
[TBL] [Abstract][Full Text] [Related]
75. Immunogenicity, clinical efficacy and safety of additional second COVID-19 booster vaccines against Omicron and its subvariants: A systematic review.
Chenchula S; Chandra MB; Adusumilli MB; Ghanta SN; Bommasani A; Kuttiappan A; Padmavathi R; Amerneni KC; Chikatipalli R; Ghanta MK; Reddy SS; Mythili Bai K; Prakash S; Jogender G; Chavan M; Balakrishnan S
Rev Med Virol; 2024 Jan; 34(1):e2515. PubMed ID: 38282403
[TBL] [Abstract][Full Text] [Related]
76. The emergence of SARS-CoV-2 Omicron subvariants: current situation and future trends.
Farahat RA; Abdelaal A; Umar TP; El-Sakka AA; Benmelouka AY; Albakri K; Ali I; Al-Ahdal T; Abdelazeem B; Sah R; Rodriguez-Morales AJ
Infez Med; 2022; 30(4):480-494. PubMed ID: 36482957
[TBL] [Abstract][Full Text] [Related]
77. Ten rapid antigen tests for SARS-CoV-2 widely differ in their ability to detect Omicron-BA.4 and -BA.5.
Krenn F; Dächert C; Badell I; Lupoli G; Öztan GN; Feng T; Schneider N; Huber M; Both H; Späth PM; Muenchhoff M; Graf A; Krebs S; Blum H; Durner J; Czibere L; Kaderali L; Keppler OT; Baldauf HM; Osterman A
Med Microbiol Immunol; 2023 Oct; 212(5):323-337. PubMed ID: 37561225
[TBL] [Abstract][Full Text] [Related]
78. Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5.
Kimura I; Yamasoba D; Tamura T; Nao N; Suzuki T; Oda Y; Mitoma S; Ito J; Nasser H; Zahradnik J; Uriu K; Fujita S; Kosugi Y; Wang L; Tsuda M; Kishimoto M; Ito H; Suzuki R; Shimizu R; Begum MM; Yoshimatsu K; Kimura KT; Sasaki J; Sasaki-Tabata K; Yamamoto Y; Nagamoto T; Kanamune J; Kobiyama K; Asakura H; Nagashima M; Sadamasu K; Yoshimura K; Shirakawa K; Takaori-Kondo A; Kuramochi J; Schreiber G; Ishii KJ; ; Hashiguchi T; Ikeda T; Saito A; Fukuhara T; Tanaka S; Matsuno K; Sato K
Cell; 2022 Oct; 185(21):3992-4007.e16. PubMed ID: 36198317
[TBL] [Abstract][Full Text] [Related]
79. Omicron variant evolution on vaccines and monoclonal antibodies.
Sabbatucci M; Vitiello A; Clemente S; Zovi A; Boccellino M; Ferrara F; Cimmino C; Langella R; Ponzo A; Stefanelli P; Rezza G
Inflammopharmacology; 2023 Aug; 31(4):1779-1788. PubMed ID: 37204696
[TBL] [Abstract][Full Text] [Related]
80. Epidemiology and analysis of SARS-CoV-2 Omicron subvariants BA.1 and 2 in Taiwan.
Liu LT; Chiou SS; Chen PC; Chen CH; Lin PC; Tsai CY; Chuang WL; Hwang SJ; Chong IW; Tsai JJ
Sci Rep; 2023 Oct; 13(1):16583. PubMed ID: 37789031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
